CHRD抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human cerebrum tissue and Mouse brain tissue lysates, Primary antibody: P02517(CHRD Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P02517(CHRD Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Chordin (CHRD) is a secreted glycoprotein that plays a critical role in embryonic development, particularly in dorsal-ventral axis formation. It acts as a bone morphogenetic protein (BMP) antagonist by binding to BMPs (e.g., BMP4) via cysteine-rich domains, preventing their interaction with cell surface receptors. This inhibition is essential for establishing neural tissue and patterning the early embryo, as demonstrated in model organisms like Xenopus and zebrafish. Chordin's activity is regulated by proteolytic cleavage (e.g., by Tolloid metalloproteases) and interactions with other BMP modulators (e.g., Noggin, Follistatin).

Antibodies targeting Chordin are widely used in developmental biology and disease research. They enable detection of Chordin expression in tissues (via immunohistochemistry, Western blot) and analysis of its localization/function during embryogenesis. In disease contexts, Chordin dysregulation has been implicated in cancer progression, skeletal disorders, and fibrosis. For example, reduced Chordin levels are associated with BMP pathway activation in certain cancers, while mutations link to brachydactyly syndromes. Anti-Chordin antibodies also facilitate mechanistic studies in BMP/TGF-β signaling pathways and evaluation of therapeutic interventions in preclinical models. Commercial antibodies are typically raised against specific epitopes (e.g., N-terminal domain) and validated for cross-reactivity across species (human, mouse, rat).